Related Experiment Video
Updated: Sep 16, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Endothelial dysfunction assessed by the endothelial activation and stress index (EASIX) predicts risk of mortality in
Bent Estler1, Hanna Fröhlich1, Tobias Täger1
1Department of Cardiology, Angiology and Pulmology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
Insights
The Endothelial Activation and Stress Index (EASIX) can predict mortality risk in chronic heart failure (CHF) patients. This novel biomarker, calculated from routine lab tests, offers valuable prognostic information for CHF management.
Area of Science:
- Cardiology
- Biomarker Discovery
- Prognostic Medicine
Background:
- Endothelial dysfunction is a hallmark of chronic heart failure (CHF) but lacks routine quantification.
- The Endothelial Activation and Stress Index (EASIX) uses creatinine, lactate dehydrogenase, and platelets to predict outcomes in various conditions.
- EASIX has shown prognostic value in conditions such as allogeneic stem cell transplantation, COVID-19, and coronary artery disease.
Purpose of the Study:
- To investigate the prognostic utility of the Endothelial Activation and Stress Index (EASIX) in patients with chronic heart failure (CHF).
- To determine if EASIX can serve as a novel biomarker for predicting mortality risk in CHF patients.
Main Methods:
- Utilized training (n=1796) and validation (n=1796) cohorts from a CHF registry.
- Assessed five-year overall survival using multivariable Cox regression, adjusting for clinical covariates.
- Employed fractional polynomials for non-linear relationships and evaluated prognostic performance with Brier score and concordance index.
Main Results:
- EASIX demonstrated a moderate correlation with NT-proBNP, NYHA stage, and LVEF.
- Increased EASIX levels were associated with a significantly higher hazard of death in both cohorts (HR per log2 increase: 1.51-1.59).
- Pre-established EASIX cut-offs independently predicted increased mortality risk (HRs ranging from 2.14 to 3.34).
Conclusions:
- The Endothelial Activation and Stress Index (EASIX) is a novel and effective biomarker for predicting mortality risk in patients with chronic heart failure (CHF).
- EASIX provides independent prognostic information, consistent across various heart failure etiologies and stages.
Background:
Endothelial dysfunction accompanies chronic heart failure (CHF) but is hard to quantify in routine practice. The Endothelial Activation and Stress Index (EASIX), calculated from creatinine, lactate dehydrogenase, and platelets, predicts mortality and complications in conditions like allogeneic stem cell transplantation, COVID-19, and coronary artery disease. Aim To evaluate if EASIX is a prognostic biomarker in patients with CHF.
Methods:
Training (n = 1796) and validation cohorts (n = 1796) included all patients from the outpatients' CHF registry of the University of Heidelberg, Germany, with available laboratory parameters for EASIX calculations at first clinical presentation. Five-year overall survival was assessed by multivariable Cox regression adjusting for age, sex, New York Heart Association (NYHA) score, etiology of heart failure, heart failure category, and NT- proBNP as covariates. Fractional polynomials modeled non-linear relationships, and prognostic performance was evaluated using the Brier score and concordance index.
Results:
EASIX moderately correlated with NT- proBNP, NYHA stage and left ventricular ejection fraction (LVEF), and associated with increased hazard of death in both cohorts (hazard ratio (HR) per log2 increase: training 1.51 (1.14-2.01), p < 0.01; validation 1.59 (1.25-2.01, p < 0.001). The effect was consistent across all etiologies, classes and stages of heart failure as assessed by fractional polynomials. Pre-established EASIX cut-offs independently predicted increased risk of mortality (cut-off 2.32: training: HR 2.14 (1.52-3.02), p < 0.001; validation: HR 3.34 (1.88-5.93), p < 0.0001). Both models (continuous and discrete EASIX values) were validated in the validation cohort using integrated Brier score and C-index.
Conclusions:
EASIX is a novel biomarker to predict risk of mortality in patients with CHF.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure VII: Nursing Interventions

